Loading...
ACER logo

Acer Therapeutics Inc.OTCPK:ACER Aktierapport

Marknadsvärde US$19.7m
Aktiekurs
n/a
1Y-30.0%
7D-5.4%
1D-0.7%
Portföljens värde
​
Utsikt

Acer Therapeutics Inc.

OTCPK:ACER Aktierapport

Börsvärde: US$19.7m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Acer Therapeutics (ACER) Aktievy

Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Mer information

ACER fundamental analys
Snöflinga Score
Värdering0/6
Framtida tillväxt5/6
Tidigare resultat0/6
Finansiell hälsa0/6
Utdelningar0/6

Belöningar

Intäkterna förväntas växa med 66.22% per år

Riskanalys

Ger mindre än 1 miljon USD i intäkter ( $0 )

Negativt eget kapital

Mycket volatil aktiekurs under de senaste 3 månaderna jämfört med US marknaden

Har mindre än 1 år av cash runway

+ 2 fler risker

ACER Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW446,008 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
B
BlackGoat
R
RockeTeller
I
Investingwilly
D
davidlsander
446,008 investors already sharing narratives
View all narratives

Acer Therapeutics Inc. Konkurrenter

Prishistorik och prestanda

Sammanfattning av aktiekursernas upp- och nedgångar samt förändringar för Acer Therapeutics
Historiska aktiekurser
Aktuell aktiekursUS$0.80
52 veckors högstaUS$4.56
52 veckors lägstaUS$0.55
Beta0.44
1 månads förändring-2.73%
3 månaders förändring21.88%
1 års förändring-30.04%
3 års förändring-70.42%
5 års förändring-96.75%
Förändring sedan börsintroduktionen-91.99%

Senaste nyheter och uppdateringar

Recent updates

Seeking Alpha • Oct 05

Acer Therapeutics to develop ACER-801 for post-traumatic stress disorder treatment

Acer Therapeutics (NASDAQ:ACER) said on Wednesday it was expanding ACER-801 into a new indication, to reduce the frequency and severity of acute stress disorder and post-traumatic stress disorder. (ACER) is trading 3.5% higher premarket. In a study conducted in thousands of genes that were activated in the brains of mice following fear conditioning events showed the drug was able to block fear memory consolidation shortly after exposure to a trauma. ACER-801 is a non-hormonal drug designed as a selective non-peptide neurokinin 3 receptor (NK3R) antagonist. "While the role of the NK3R pathway in the hypothalamus to manage thermoregulation is well-established in clinical trials, this opportunity explores an entirely different mechanism of action for the drug. We look forward to presenting our clinical development plan for ACER-801 for the reduction of frequency and severity of PTSD in the near future," the company said. Acute stress disorder refers to the body’s immediate response to trauma, whereas PTSD is defined as the long-term effects of trauma. The company is also developing the drug for induced Vasomotor Symptoms, which is hot flashes, flushing, and night sweats — that tend to occur in or around menopause.
Seeking Alpha • Aug 12

Acer, Relief's metabolic disorder therapy ACER-001 gets orphan drug status in EU

The European Commission granted orphan medicinal product designation to Acer Therapeutics (NASDAQ:ACER) and Relief Therapeutics' (OTCQB:RLFTF) (OTCQB:RLFTY) ACER-001 (sodium phenylbutyrate) to treat patients with Maple Syrup Urine Disease (MSUD). ACER-001 was had received the U.S. Food and Drug Administration's (FDA) orphan drug designation for MSUD in 2014, the companies said in an Aug. 12 press release. MSUD is a rare genetic metabolic disorder characterized by deficiency of an enzyme complex which is required to break down certain amino acids in the body. In the EU, the orphan drug status is granted to therapies aimed at treating or preventing a serious or life-threatening disease which affects not more than five in 10K people in the EU. The designation has benefits, including up to 10 years of market exclusivity for the product, if approved. ACER +6.76% to $1.58 premarket Aug. 12
Seeking Alpha • Jul 28

FDA accepts Acer's resubmitted U.S. marketing application for urea cycle disorder therapy

Acer Therapeutics (NASDAQ:ACER) and partner Relief Therapeutics (OTCQB:RLFTF) (OTCQB:RLFTY) on Thursday said the U.S. Food and Drug Administration (FDA) had accepted the companies' resubmission of their new drug application for their ACER-001 treatment for patients with urea cycle disorders. The FDA designated the new drug application (NDA) as a class 2 resubmission and said it would review the application by Jan. 15, 2023, or the so-called Prescription Drug User Fee Act date. Despite the news, ACER stock had fallen 4.2% to $1.37 in premarket trading. The FDA's acceptance of the NDA comes 10 days after ACER and RLFTF resubmitted the application. The NDA had been initially declined by the FDA in June as the agency's field investigator had been unable to complete inspection of ACER's third-party contract packaging manufacturer.
Seeking Alpha • Jul 18

Acer resubmits U.S. marketing application for urea cycle disorder therapy

Newton, Massachusetts-based Acer Therapeutics (NASDAQ:ACER) announced on Monday that the company resubmitted its New Drug Application (NDA) seeking FDA approval of ACER-001 oral suspension for the treatment of patients with urea cycle disorders (UCDs). Also known as sodium phenylbutyrate, ACER-001 is undergoing studies as a treatment for various inborn errors of metabolism such as UCDs. In June, Acer (ACER) announced that the FDA issued a Complete Response Letter (CRL), rejecting the marketing approval of the drug, citing the need for satisfactory inspection of its third-party contract packaging manufacturer. In the resubmission, the company has informed the FDA that the contract manufacturer in question is ready for inspections. In addition to labeling and other standard updates to the original filing, the resubmitted NDA included the nonclinical info that the FDA requested but categorized as “not an approvability issue” in the CRL. A decision on the acceptance of the NDA is expected within 14 calendar days of the submission. Last month, the shares of Acer (ACER) and its partner Relief Therapeutics (OTCQB:RLFTF) fell on the announcement of FDA rejection of ACER-001.
Analysartikel • Feb 11

Companies Like Acer Therapeutics (NASDAQ:ACER) Can Afford To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Aug 31

Acer Therapeutics: Deriving Value By Developing Therapies For Rare Diseases

Acer Therapeutics is a pharmaceutical company that acquires, develops and seeks to commercialize therapies for serious, rare, and life-threatening diseases. Acer submitted an NDA for its lead drug candidate ACER-001 for treatment of UCDs in early August. Acer expects notification regarding potential acceptance for filing from the FDA approximately 60 days after NDA submission and subsequent substantive review. If approved, Acer could launch ACER-001 in mid-2022. Other than UCDs, Acer is developing therapies for MSUD, iVMS, vEDS, and infectious diseases. All these diseases have a market that is niche and untapped, characterized by low competition. Assuming a base case revenue of $40 million in 2022 and a P/S ratio of 5.0x, the company’s intrinsic value would be ~$122 million or $8.70 per share, indicating an upside close to 3.5x.
Analysartikel • May 20

We're Not Very Worried About Acer Therapeutics' (NASDAQ:ACER) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysartikel • Feb 25

Need To Know: Acer Therapeutics Inc. (NASDAQ:ACER) Insiders Have Been Buying Shares

We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also...

Aktieägarnas avkastning

ACERUS PharmaceuticalsUS Marknad
7D-5.4%-0.6%-1.6%
1Y-30.0%45.2%12.1%

Avkastning vs industri: ACER presterade sämre än US Pharmaceuticals branschen som gav 45.2 % under det senaste året.

Avkastning vs Marknaden: ACER presterade sämre än US marknaden som gav 12.1 % under det senaste året.

Prisvolatilitet

Is ACER's price volatile compared to industry and market?
ACER volatility
ACER Average Weekly Movement32.3%
Pharmaceuticals Industry Average Movement8.5%
Market Average Movement6.8%
10% most volatile stocks in US Market15.2%
10% least volatile stocks in US Market2.9%

Stabil aktiekurs: ACER s aktiekurs har varit volatil under de senaste 3 månaderna jämfört med marknaden för US.

Volatilitet över tid: ACER s veckovolatilitet har ökat från 23% till 32% under det senaste året.

Om företaget

GrundadAnställdaVD OCH KONCERNCHEFWebbplats
199130Chris Schellingwww.acertx.com

Acer Therapeutics Inc. Sammanfattning av grunderna

Hur förhåller sig Acer Therapeutics:s resultat och omsättning till dess börsvärde?
ACER grundläggande statistik
BörsvärdeUS$19.68m
Vinst(TTM)-US$38.76m
Intäkter(TTM)n/a
0.0x
P/S-förhållande
-0.5x
P/E-förhållande

Är ACER övervärderat?

Se Verkligt värde och värderingsanalys

Resultat & intäkter

Viktig lönsamhetsstatistik från den senaste resultatrapporten (TTM)
ACER resultaträkning (TTM)
IntäkterUS$0
Kostnad för intäkterUS$0
BruttovinstUS$0
Övriga kostnaderUS$38.76m
Intäkter-US$38.76m

Senast redovisade vinst

Jun 30, 2023

Nästa vinstdatum

n/a

Vinst per aktie (EPS)-1.58
Bruttomarginal0.00%
Nettovinstmarginal0.00%
Skuld/egenkapitalförhållande-96.4%

Hur har ACER utvecklats på lång sikt?

Se historisk utveckling och jämförelse

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2023/11/20 10:43
Aktiekurs vid dagens slut2023/11/17 00:00
Intäkter2023/06/30
Årlig intjäning2022/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.

Lär dig mer om det som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Acer Therapeutics Inc. bevakas av 8 analytiker. 2 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Kumaraguru RajaBrookline Capital Markets
Constantine DavidesD. Boral Capital LLC.
Vernon BernardinoH.C. Wainwright & Co.